Fig. 1 · Structure

Documents & Downloads

Fosbretabulin disodium (CA4P)

Cat. No. A13081 CAS 168555-66-6

microtubule-targeting agent

Fosbretabulin disodium is the disodium salt of a water-soluble phosphate derivative of a natural stilbenoid phenol derived from the African bush willow (Combretum caffrum) with potential vascular disrupting and antineoplastic activities.

In Stock

Publications for Fosbretabulin disodium

1 publication citing this product

  1. Valeria Sidorenko, .et al. , Sci Rep, 2024, Jul 30;14(1):17513 PMID: 39080306

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In HUVEC, combretastatin A-4 disodium phosphate was reported to disrupt F-actin organization and tubulin microtubules at 0.40 µM within approximately 1 h. These are cellular observations; this experiment does not establish a purified-tubulin binding affinity or an enzymatic conversion rate. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Tubulin (Cell-free assay) 2.4 μM

Cellular Effect

Cell Line Activity Value Description Reference
A2780 GI50 0.32 μM Antiproliferative activity against human A2780 cells after 48 hrs by MTT assay [PMID: 30580241]
A-375 IC50 0.0016 μM Growth inhibition of human A375 cells measured after 48 hrs by MTS assay [PMID: 27100701]
A549 IC50 0.0234 μM Growth inhibition of human A549 cells by MTS assay [PMID: 27100701]
A549 GI50 0.16 μM Antiproliferative activity against human A549 cells after 48 hrs by MTT assay [PMID: 30580241]
A549 IC50 0.4 μM Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay [PMID: 30108925]
Bel-7402 IC50 0.04 μM Antiproliferative activity against human Bel-7402 cells measured after 48 hrs by SRB assay [PMID: 32113125]
BXPC-3 GI50 0.23 μg/mL Growth inhibition of human BxPC3 cells after 48 hrs by sulforhodamine B assay [PMID: 22324723]
BXPC-3 GI50 0.23 μg/mL Antitumor activity against human BxPC3 cells by sulforhodamine B assay [PMID: 19228038]
Caov-3 cell line IC50 13.11 nM Antiproliferative activity against human Caov3 cells measured after 96 hrs by Celltiter-Glo assay [PMID: 27718473]
CCRF-CEM IC50 0.011 μM Antiproliferative activity against human CEM cells measured after 96 hrs by Coulter counter method [PMID: 30921759]
CCRF-CEM IC50 0.011 μM Antiproliferative activity against human CEM cells after 96 hrs by coulter counting method [PMID: 29471122]
CCRF-CEM IC50 95 nM Antiproliferative activity against human CEM cells after 96 hrs by Coulter counter method [PMID: 25626146]
DU-145 GI50 0.0007 μg/mL Antitumor activity against human DU145 cells by sulforhodamine B assay [PMID: 19228038]
DU-145 IC50 0.0014 μM Growth inhibition of human DU145 cells measured after 48 hrs by MTS assay [PMID: 27100701]
DU-145 GI50 0.00323 μM Cytotoxicity against human DU145 cells assessed as growth inhibition measured after 48 hrs by SRB assay [PMID: 31059248]
DU-145 GI50 0.00323 μM Cytotoxicity against human DU145 cells after 48 hrs by SRB assay [PMID: 24183586]
DU-145 GI50 0.0072 μg/mL Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay [PMID: 22324723]
DU-145 GI50 0.016 μM Cytotoxicity against human DU145 cells by SRB assay [PMID: 24016002]
HCT-116 IC50 0.0016 μM Growth inhibition of human HCT116 cells measured after 48 hrs by MTS assay [PMID: 27100701]
HCT-116 IC50 0.24 μM Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay [PMID: 30108925]
HeLa IC50 0.00043 μM Cytotoxicity against human HeLa cells by MTT assay

21 records · Scroll to view more

Fosbretabulin disodium (CA4P) Research Summary

This section summarizes 1 in vitro study and 2 in vivo studies of Fosbretabulin disodium (CA4P) from 2 published references. In vitro models include primary human umbilical vein endothelial cells (HUVEC).

Fosbretabulin disodium (CA4P) In Vitro Studies

The same paper reported HUVEC viability of 63.1% (s.d. 2.82) after 24 h at 0.40 µM disodium phosphate. Although the authors called this concentration non-cytotoxic, the viability result limits that description and should be considered when interpreting cytoskeletal effects. [1]

Endothelial cytoskeletal disruption with viability context

Cell-based study · Primary human umbilical vein endothelial cells (HUVEC) [1]

The authors report disruption of F-actin and tubulin microtubules about 1 h after 0.40 µM disodium phosphate treatment. At the same concentration, a separate 24-h neutral red viability assessment gave 63.1% survival. The paper’s designation of this concentration as non-cytotoxic should therefore be interpreted cautiously.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
F-actin and tubulin microtubule organizationQualitative microscopy Complete cytoskeletal disorganization reported approximately 1 h after treatment; described as uniform across the monolayer[1]
HUVEC viability after 24 h at 0.40 µM disodium phosphateNeutral red viability 63.1% (s.d. 2.82)[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.40 µM
Exposure duration
Approximately 1 h for cytoskeletal changes; 24 h exposure for the supporting viability assessment
Method
Rhodamine–phalloidin F-actin staining and anti-β-tubulin immunoperoxidase staining; neutral red viability assay
Vehicle
Cytoskeletal controls were untreated; neutral red methods describe medium or DMSO comparators, without a prodrug-specific vehicle assignment.
Reported limits
Staining replicate count and prodrug-specific solvent/control assignment are not specified in the read methods. Fig.7 illustrates parent CA4 at 0.31 µM, not the prodrug.
Methods and source locations

Compound reported in the paper: Combretastatin A-4 disodium phosphate; Compound label in the paper: CA4P

Applies to the reported disodium phosphate material and model; does not validate an Adooq lot or equate the phosphate prodrug with parent CA4.

pp.1320–1321, HUVEC culture, neutral red assay, F-actin staining and Tubulin staining; pp.1323–1324, In vitro studies and Effects on HUVEC cytoskeleton; Fig.7 caption p.1325

F-actin and tubulin microtubule organization: F-actin and β-tubulin staining; untreated controls processed identically — pp.1320–1321, HUVEC culture, neutral red assay, F-actin staining and Tubulin staining; pp.1323–1324, In vitro studies and Effects on HUVEC cytoskeleton; Fig.7 caption p.1325

HUVEC viability after 24 h at 0.40 µM disodium phosphate: Neutral red uptake; methods state each experiment was performed at least in triplicate; biological replicate count is not separately specified — p.1320 HUVEC neutral red assay; p.1323 In vitro studies

Fosbretabulin disodium (CA4P) In Vivo Studies

In NMRI mice bearing orthotopic MAC 15 colon tumors, a single intraperitoneal dose of 100 mg kg−1 disodium phosphate produced 97.34 ± 9.99% necrotic area at 24 h, versus 4.21 ± 6.74% in controls (mean ± s.d.; P < 0.001). Viable peripheral tumor remained, and avascular pulmonary deposits in prodrug-treated mice showed no necrosis. [1]

In male Sprague Dawley rats, a single intravenous 120 mg/kg dose of CA4DP caused myocardial injury and reduced stroke and cardiac indices at 72 h. Oral tadalafil pretreatment (5 mg/kg, 2 h earlier) attenuated cardiac injury, but lesions persisted and the stroke-index difference versus CA4DP alone was not significant. This high-dose toxicology result limits general claims of tolerability. [2]

Orthotopic tumor necrosis and an avascular-site limitation

Animal study · NMRI mice, 6–8 weeks; orthotopic MAC 15 colon adenocarcinoma and associated pulmonary deposits [1]

At 24 h after a single 100 mg kg−1 intraperitoneal dose, orthotopic tumors had extensive necrosis versus controls. A viable peripheral rim remained, and avascular lung deposits were unaffected. These observations support a vascularly dependent antitumor effect rather than complete tumor eradication.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Necrotic area of orthotopic MAC 15 tumors at 24 hMean percentage ± s.d. Treated 97.34 ± 9.99%; control 4.21 ± 6.74%; P < 0.001[1]
Necrosis in avascular pulmonary tumor deposits after prodrug treatmentQualitative histology No signs of necrosis in lung deposits in three prodrug-treated mice[1]
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Disodium phosphate-treated orthotopic tumors
100 mg kg−1
Control tumors in Table 3Necrotic area 97.34 ± 9.99% (mean ± s.d.); viable peripheral tumor remained. The three prodrug-treated mice with lung deposits had no signs of necrosis in those avascular deposits.[1]
Orthotopic tumor controlsComparator for disodium phosphate treatmentNecrotic area 4.21 ± 6.74% (mean ± s.d.).[1]
Disodium phosphate-treated orthotopic tumors
Model: NMRI mice bearing orthotopic MAC 15 colon tumors; three treated mice stated
Route: Intraperitoneal
Frequency: Single dose
Treatment course: 24-h histological endpoint
Vehicle: Saline
Reported limits: Control group size is not specified for Table 3; sex is not specified in Animals.
Orthotopic tumor controls
Model: NMRI mice bearing orthotopic MAC 15 colon tumors
Treatment course: 24-h comparison
Reported limits: Table 3 does not state control group size or explicit control injection details. Saline is the prodrug formulation, but a saline injection is not imputed to this arm.
Methods and source locations

Compound reported in the paper: Combretastatin A-4 disodium phosphate; Compound label in the paper: CA4P

Applies to the reported disodium phosphate material and model; does not validate an Adooq lot or equate the phosphate prodrug with parent CA4.

p.1319, Compounds and Histological assessment; p.1321 Table 3; pp.1322–1323 Orthotopic model studies (including lung deposits)

Necrotic area of orthotopic MAC 15 tumors at 24 h: Image analysis of histological sections; treated n=3 in Results; endpoint-specific statistical test not assigned (shared methods list Mann–Whitney U or Student’s t-test) — p.1321 Table 3; pp.1319–1320 Histological assessment and Statistical analysis; p.1322 Orthotopic model studies

Necrosis in avascular pulmonary tumor deposits after prodrug treatment: Microscopic examination; pulmonary deposits characterized as avascular in the same orthotopic model — pp.1322–1323 Orthotopic model studies; Fig.5 characterizes avascular lung deposits; Fig.6 illustrates parent CA4, not CA4P

Disodium phosphate-treated orthotopic tumors · p.1319, Compounds and Histological assessment; p.1321 Table 3; pp.1322–1323 Orthotopic model studies (including lung deposits)

Orthotopic tumor controls · p.1319, Compounds and Histological assessment; p.1321 Table 3; pp.1322–1323 Orthotopic model studies (including lung deposits)

Acute cardiac injury and incomplete protection by tadalafil

Animal study · Six-week-old male Sprague Dawley rats (Crl:CD(SD)); vehicle n=5, tadalafil n=5, CA4DP n=4, CA4DP+tadalafil n=4 [2]

At a deliberately cardiotoxic dose, CA4DP reduced cardiac function and caused myocardial lesions at 72 h. Tadalafil pretreatment attenuated injury but did not eliminate histological lesions or significantly improve stroke index relative to CA4DP alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Stroke Index and Cardiac Index at 72 hDirectional comparison and significance CA4DP lower than vehicle for SI and CI (p<0.05); combination higher than CA4DP for CI (p<0.05), but not significantly different for SI[2]
Myocardial lesions 72 h after CA4DPQualitative histopathology Cardiomyocyte necrosis and inflammatory infiltration, pericapillary edema and endothelial pyknosis; milder but still present with tadalafil pretreatment[2]
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vehicle
No CA4DP
Baseline comparison for CA4DPVehicle comparator for stroke and cardiac indices.[2]
CA4DP alone
120 mg/kg CA4DP
Vehicle groupLower stroke and cardiac indices versus vehicle (p<0.05); cardiomyocyte necrosis, inflammatory infiltration, pericapillary edema and capillary endothelial pyknosis.[2]
Tadalafil alone
5 mg/kg tadalafil; no CA4DP
Vehicle and CA4DP groupsTadalafil comparator included in the cardiac index and stroke index analyses.[2]
Tadalafil pretreatment plus CA4DP
5 mg/kg tadalafil followed 2 h later by 120 mg/kg CA4DP
CA4DP aloneCardiac index significantly higher than CA4DP alone (p<0.05); stroke index difference was not significant. Histological lesions persisted but were milder.[2]
Vehicle
Model: Six-week-old male Sprague Dawley rats (Crl:CD(SD)); vehicle n=5, tadalafil n=5, CA4DP n=4, CA4DP+tadalafil n=4
Route: Oral vehicle, followed 2 h later by intravenous saline
Frequency: Single administrations
Treatment course: 72 h after saline for cardiac endpoints
Vehicle: 0.5% methylcellulose orally; saline intravenously
CA4DP alone
Model: Six-week-old male Sprague Dawley rats (Crl:CD(SD)); vehicle n=5, tadalafil n=5, CA4DP n=4, CA4DP+tadalafil n=4
Route: Intravenous bolus via caudal vein, 2 h after oral vehicle
Frequency: Single CA4DP dose
Treatment course: 72 h after CA4DP
Vehicle: Saline; oral pretreatment with 0.5% methylcellulose
Tadalafil alone
Model: Six-week-old male Sprague Dawley rats (Crl:CD(SD)); vehicle n=5, tadalafil n=5, CA4DP n=4, CA4DP+tadalafil n=4
Route: Oral tadalafil; intravenous saline 2 h later
Frequency: Single administrations
Treatment course: 72 h after intravenous saline
Vehicle: Tadalafil in 0.5% methylcellulose; saline
Tadalafil pretreatment plus CA4DP
Model: Six-week-old male Sprague Dawley rats (Crl:CD(SD)); vehicle n=5, tadalafil n=5, CA4DP n=4, CA4DP+tadalafil n=4
Route: Oral tadalafil then intravenous CA4DP bolus via caudal vein
Frequency: Single dose of each drug
Treatment course: 72 h after CA4DP
Vehicle: Tadalafil in 0.5% methylcellulose; CA4DP in saline
Methods and source locations

Compound reported in the paper: Combretastatin A-4 disodium phosphate; Compound label in the paper: CA4DP

Applies to the reported disodium phosphate material and model; does not validate an Adooq lot or equate the phosphate prodrug with parent CA4.

Materials and Methods, introductory paragraph and Evaluation of cardiotoxicity using rats (sec3); Results, Evaluation of cardiotoxicity using rats (sec7); Fig.1B–C and Fig.2 with captions

Stroke Index and Cardiac Index at 72 h: Echocardiography under isoflurane; indices normalized to body surface area; Tukey’s test. Group sizes 5/5/4/4 for vehicle/tadalafil/CA4DP/combination. — sec3 and sec5; sec7; Fig.1B–C (printed p.154)

Myocardial lesions 72 h after CA4DP: H&E histology and Iba-1 immunostaining in the same cohort as echocardiography — sec3 and sec7; Fig.2A–F (printed p.155)

Vehicle · Materials and Methods, introductory paragraph and Evaluation of cardiotoxicity using rats (sec3); Results, Evaluation of cardiotoxicity using rats (sec7); Fig.1B–C and Fig.2 with captions

CA4DP alone · Materials and Methods, introductory paragraph and Evaluation of cardiotoxicity using rats (sec3); Results, Evaluation of cardiotoxicity using rats (sec7); Fig.1B–C and Fig.2 with captions

Tadalafil alone · Materials and Methods, introductory paragraph and Evaluation of cardiotoxicity using rats (sec3); Results, Evaluation of cardiotoxicity using rats (sec7); Fig.1B–C and Fig.2 with captions

Tadalafil pretreatment plus CA4DP · Materials and Methods, introductory paragraph and Evaluation of cardiotoxicity using rats (sec3); Results, Evaluation of cardiotoxicity using rats (sec7); Fig.1B–C and Fig.2 with captions

Specifications

Manufacturer Adooq Bioscience
CAS Number 168555-66-6
Alternate CAS 222030-63-9
Applications microtubule-targeting agent
Formula C18H19Na2O8P
Molecular Weight 440.29
Synonyms CA4P
SMILES
COC1=C(C=C(C=C1)/C=C\C2=CC(=C(C(=C2)OC)OC)OC)OP(=O)([O-])[O-].[Na+].[Na+]

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Insoluble
Water 25 mg/mL (56.78 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
Saline with a few drops of 5% Na2CO3

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Fosbretabulin disodium (CA4P) Research References

  1. [1] K Grosios, S E Holwell, A T McGown, et al. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug British Journal of Cancer (1999). PMID: 10604728 DOI: 10.1038/sj.bjc.6692174 Source material
  2. [2] Yoshiyasu Nagashima, Ryota Tochinai, Shin-ichi Sekizawa, et al. Pretreatment with tadalafil attenuates cardiotoxicity induced by combretastatin A4 disodium phosphate in rats Journal of Toxicologic Pathology (2023). PMID: 37577366 DOI: 10.1293/tox.2022-0143 Source material

Publications

1 publication citing this product

  1. Valeria Sidorenko, .et al. , Sci Rep, 2024, Jul 30;14(1):17513 PMID: 39080306

Added to your cart

View Cart Checkout
Loading...